Compounds > perifosine
Page last updated: 2024-09-04

perifosine and dasatinib

perifosine has been researched along with dasatinib in 6 studies

Compound Research Comparison

Studies
(perifosine)		Trials
(perifosine)		Recent Studies (post-2010)
(perifosine)		Studies
(dasatinib)		Trials
(dasatinib)		Recent Studies (post-2010) (dasatinib)
245311402,7072162,081

Protein Interaction Comparison

ProteinTaxonomyperifosine (IC50)dasatinib (IC50)
Aurora kinase AHomo sapiens (human)2.633
Mitogen-activated protein kinase 13Homo sapiens (human)0.1
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.109
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.9374
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.1922
Epidermal growth factor receptorHomo sapiens (human)0.7144
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.164
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.71
Tyrosine-protein kinase LckHomo sapiens (human)0.0015
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)0.0004
Tyrosine-protein kinase FynHomo sapiens (human)0.0012
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0078
Tyrosine-protein kinase YesHomo sapiens (human)0.0006
Tyrosine-protein kinase LynHomo sapiens (human)0.0012
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.2665
Tyrosine-protein kinase HCKHomo sapiens (human)0.001
Platelet-derived growth factor receptor betaHomo sapiens (human)0.028
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0276
Breakpoint cluster region proteinHomo sapiens (human)0.4946
Fibroblast growth factor receptor 1Homo sapiens (human)0.88
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0015
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0365
Tyrosine-protein kinase BlkMus musculus (house mouse)0.008
Ephrin type-A receptor 2Homo sapiens (human)0.0689
Ephrin type-B receptor 2Homo sapiens (human)0.0044
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.36
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)1.7
Tyrosine-protein kinase CSKHomo sapiens (human)0.0013
Tyrosine-protein kinase TecHomo sapiens (human)0.297
Tyrosine-protein kinase TXKHomo sapiens (human)0.0003
Tyrosine-protein kinase SYKHomo sapiens (human)4.82
Casein kinase I isoform alphaHomo sapiens (human)0.001
LIM domain kinase 1Homo sapiens (human)0.6097
LIM domain kinase 2Homo sapiens (human)0.5186
Mitogen-activated protein kinase 12Homo sapiens (human)0.1
Ephrin type-B receptor 4Homo sapiens (human)0.001
Serine/threonine-protein kinase SIK1Homo sapiens (human)0.001
Myelin transcription factor 1Homo sapiens (human)0.063
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)1.7
Tyrosine-protein kinase BTKHomo sapiens (human)0.0036
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0143
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)0.228
Protein-tyrosine kinase 6Homo sapiens (human)0.0071
Mitogen-activated protein kinase 11Homo sapiens (human)0.1
Mitogen-activated protein kinase 14Homo sapiens (human)0.1
Discoidin domain-containing receptor 2Homo sapiens (human)0.1127
Aurora kinase BHomo sapiens (human)6.485
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)0.104
Serine/threonine-protein kinase SIK2Homo sapiens (human)0.003
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2
Serine/threonine-protein kinase SIK3Homo sapiens (human)0.005

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D1
Ho, SL; Lavi, E; Singh, R; Souweidane, MM; Zhou, Z1
Ho, SL; Pisapia, DJ; Singh, R; Souweidane, MM; Zhou, Z1
Cartagena-Rivera, AX; Chadwick, RS; Logue, JS1

Other Studies

6 other study(ies) available for perifosine and dasatinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    British journal of haematology, 2013, Volume: 161, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured

2013
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2015, Volume: 31, Issue:2

    Topics: Animals; Antineoplastic Agents; Brain Stem; Convection; Dasatinib; Drug Delivery Systems; Everolimus; Female; Infusions, Intraventricular; Phosphorylcholine; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sirolimus; Thiazoles

2015
Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2015, Volume: 31, Issue:4

    Topics: Animals; Animals, Newborn; Brain Stem; Cell Line, Tumor; Cell Proliferation; Convection; Dasatinib; Dose-Response Relationship, Drug; Drug Delivery Systems; Everolimus; Glioma; Intracranial Hemorrhages; Mice; Phosphorylcholine; Protein Kinase Inhibitors; Time Factors

2015
c-Src activity is differentially required by cancer cell motility modes.
    Oncogene, 2018, Volume: 37, Issue:16

    Topics: Actins; Amino Acid Substitution; Butadienes; Cell Adhesion; Cell Movement; Dasatinib; Humans; Imidazoles; Mutant Proteins; Neoplasms; Nitriles; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinolines; Tumor Cells, Cultured

2018